Kornimate/medical-research-clean huggingface dataset:
surgical and oncological outcomes in patients with ulcerative colitis-associated rectal cancer

Conditions: Ulcerative Colitis; Rectal Cancer

Summary: this is a retrospective observational study to investigate the short-term surgical outcomes, and long-term oncological outcomes of patients diagnosed with ulcerative colitis and rectal cancer.

inflammatory bowel disease (ibd) is a risk factor for the development of colorectal cancer (crc). despite improved targeted screening and timely prophylactic resection, up to 15% of all ibd-related mortality can be attributed to crc. previous reports suggest that ibd patients present with crc at an earlier age and with more advanced disease than those with sporadic crc. the literature is limited, however, with respect to colitis-associated rectal cancer (carc), which has unique considerations such as surgical approach and the use of neoadjuvant therapy. although total proctocolectomy is generally the procedure of choice for those with carc, recent reports reported acceptable oncological outcomes after ileal pouch-anal anastomosis (ipaa) and ileorectal anastomosis (ira). the impact of the type of surgical procedure on the oncologic outcome in patients with carc is not well defined. the aim of this study is to investigate short-term surgical outcomes (postoperative complications at 30 days after surgery) and long-term oncological outcomes (disease-free survival) of carc patients undergoing different surgical approaches.

Eligibility criteria:
inclusion criteria: * patients diagnosed with ulcerative colitis; * patients diagnosed with rectal cancer (within 15 cm from the anal verge); * patients who underwent surgery for rectal cancer between january 2004 and january 2020; * all type of surgery will be included; * surgery in elective and emergency settings. exclusion criteria: * patients aged\<18 years; * patients with a diagnosis of undetermined colitis; * insufficient follow-up data.

Keywords: ulcerative colitis rectal cancer
pain control in elderly hip fracture patients: is intravenous acetaminophen superior to oral administration?

Conditions: Hip Fracture

Summary: the primary objective is to determine if intravenous acetaminophen decreases pain scores and the amount of morphine equivalence received as compared to oral acetaminophen in patients greater than 65 years old after sustaining a hip fracture.

surgeons involved in this research agree to the randomization of patients into one of two groups. after informed consent, patients will be randomly assigned in a 1:1 ratio to the treatment group or the control group. group 1: this group will serve as the control group, and will be scheduled to receive one gram (1g) acetaminophen po every 8 hours. group 2: this group will serve as the treatment group, and will be scheduled to receive one gram (1g) acetaminophen iv every 8 hours the standardized pain control protocol for hip fracture patients will be initiated for all patients. the pain protocol will be initiated at hospital admission, and after three postoperative doses of the group assigned acetaminophen all patients will be switched to one gram scheduled acetaminophen po in preparation for hospital discharge.

Eligibility criteria:
inclusion criteria: 1. acute, isolated, unilateral femoral neck, intertrochanteric, and per trochanteric hip fractures confirmed by anteroposterior/lateral hip radiographs, computed tomography, or magnetic resonance imaging (mri). 2. age ≥ 65 years. 3. low energy mechanism. 4. hip fracture fixation performed within 48 hours of injury. 5. english speaking. 6. anticipated medical optimization for operative fixation. 7. no other major trauma. exclusion criteria: 1. unable to provide informed consent (dementia, limited decision making capacity) 2. admitted by medical service for significant co-morbidities 3. retained hardware around the affected hip 4. infection around the affected hip 5. transfer patients with a length of stay \> 24 hours at the transferring hospital 6. known allergy to acetaminophen 7. current use of narcotics 8. receiving a regional anesthetic block at any point during the hospitalization 9. known history of hepatic disease (hepatitis, cirrhosis) 10. weight \< 50kg 11. prisoner 12. involved in another clinical trial that would interfere with the intervention of this study
impact of procalcitonin on the management of children aged 1 to 36 month presenting with a fever without a source

Conditions: Procalcitonin; Fever Without Source; Bacterial Infection; Bacteremia

Summary: serious bacterial infections are often difficult to detect in children with fever without source. procalcitonin is a better blood marker of infection than white blood cell count and possibly than c-reactive protein. this could lead to a reduction in antibiotic prescription. our objective is to evaluate the impact of procalcitonin result on antibiotic prescription in children 1 to 36 month old with fever without source and our hypothesis is that it will lower the antibiotic prescription rate


Eligibility criteria:
inclusion criteria: * children 1-36 months * with rectal temperature \>38.0 c * and no identified source of infection after history and physical examination exclusion criteria: * acquired or congenital immunodeficiency

Keywords: procalcitonin antibiotic fever without source fever without focus bacteremia urinary tract infection
the effects of dietary supplement of coenzyme q10（coq10） on dyslipidemia

Conditions: Dyslipidemia

Summary: in previous study the investigators found that coq10 can improve cholesterol efflux from macrophages in cell model, apoe mice model and small-scale of healthy volunteers. in addition, coq10 has strong antioxidant activity and is an essential factor of mitochondria electron transport chain. so the investigators hypothesize that coq10 may have some health promotion effect on dyslipidemia, risk factor of atherosclerosis and other cardiovascular diseases. on this purpose, the investigators are going to recruit 150 dyslipidemia patients to supply coq10+vitamin e or coq10 alone or placebo in different doses for 24 weeks to explore the effects of coq10 on cholesterol efflux and lipid profiles on dyslipidemia.


Eligibility criteria:
inclusion criteria: * the subjects were considered to have dyslipidemia if they met 2 of the following 4 criteria: * fasting total cholesterol concentration\>200 mg/dl, * fasting triglyceride concentration\>150mg/dl, * fasting ldl-cholesterol concentrations\>100 mg/dl, or * fasting hdl-cholesterol concentrations\>40 mg/dl. exclusion criteria: * history of cvd or other severe chronic disease or use of any drugs known to affect lipid metabolism. * use any antioxidant such as vitamin e, vitamin c,phytochemicals and coenzyme q10 within two months before trial. * pregnant or lactating women

Keywords: cholesterol efflux dyslipidemia
selective cox-ii inhibitor as a palliative therapy in patients with r1 or r2 resection for disseminated stomach cancer - a multi-centre prospective randomized controlled trial

Conditions: Cancer of Stomach

Summary: the purpose of this study is to investigate the effect of selective cox-ii inhibitor in patients with regionally disseminated stomach cancer treated by palliative resection (so called r1 or r2 gastrectomy).

cyclo-oxygenase (cox) is a family of enzymes regulating the conversion of arachidonic acid to prostaglandins. cox-ii is an inducible enzyme, which expresses excessively when there are stimuli such as inflammation or hypergastrinaemia. up to 40% of patients with stomach cancer are found to have disseminated disease during surgical exploration. while palliative resection could offer a marginal benefit in the survival of these patients, almost all patients will die of progression of disease within a short time span. palliative chemotherapy has been used in the past. however, there is no evidence that the chemotherapy can confer any survival advantages, and the side-effects and toxicity of the treatment may indeed compromise the quality of life of these patients. with a better understanding of the relation between cox-ii and stomach cancer, it may be possible to suppress the progression of the residual cancer cells after the palliative resection by giving the patients selective cox-ii inhibitors.

Eligibility criteria:
inclusion criteria: * stomach cancer with peritoneal or lymphatic spread beyond the scope of curative resection * palliative resection can be performed * normal rft exclusion criteria: * solid organ metastases * poor performance status * on long-term aspirin or nsaid * renal or hepatic dysfunction * bleeding disorder * hypersensitive to cox-ii inhibitors/aspirin/nsaid * no history of myocardial infarct or stroke
oral estradiol valerate versus oral contraceptive pill in invitro fertilization patients

Conditions: Infertility

Summary: the recent controversy regarding the use of pill for cycle planning in gnrh antagonists ivf cycle has driven the search for new ways to plan ivf cycles in order to avoid weekends or to equally distribute the workload. recently, mid-late luteal phase oral estrogens seem to be as good as the pill. the investigators will compare ocp vs oral estrogens to plan the initiation of ivf cycles.


Eligibility criteria:
inclusion criteria: * 1st or 2nd ivf cycle * bmi \<30 kg/m2 * regular menstrual cycles * basal fsh \<10iu and e2 \<60pg/ml exclusion criteria: * polycystic ovaries * endometriosis * previous ovarian surgery * previous low ovarian response
immune responses to bcg vaccination in malawi and the uk

Conditions: Immunity, Cellular; Hypersensitivity, Delayed Type

Summary: bcg vaccination has been found to provide greater protection against tb in the uk than in malawi. this study compares immune responses in bcg-vaccinated and unvaccinated teenagers and young adults in malawi and in the uk.


Eligibility criteria:
inclusion criteria: * bcg unvaccinated * hiv negative * not pregnant * informed consent exclusion criteria: * hiv positive * pregnant * seriously ill
disco - influence of a simple information booklet on the evolution of acute low back pain (lbp)

Conditions: Acute Low Back Pain

Summary: to assess the impact of standardized written information on outcome in acute lbp.

a 3-month prospective, controlled study with a quasi-experimental design (i.e., a nonrandomized controlled sample with geographic stratification \[30 areas\]). control and intervention areas are selected for their similarities in rural-to-urban distribution of the population and patients' access to gps and to minimize risk of overlap between areas.

Eligibility criteria:
inclusion criteria: * each gp have to enroll up to 4 patients with acute lbp. exclusion criteria: patients are excluded if they 1. are less than 18 years old; 2. have pain for more than 4 weeks; 3. have pain intensity for the previous 24 hours less than 3 on a 11-point numeric scale (0= no pain, 10=maximal pain); 4. have sciatica; 5. have had a previous episode of acute lbp during the last 12 months; 6. have no occupational activities; 7. have consulted another practitioner for the same episode of back pain; 8. are pregnant; 9. have back pain related to infection, tumor, or inflammatory disease; or (j) have previously undergone back surgery. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
a study comparing efficacy and safety of abt-493/abt-530 to sofosbuvir dosed with daclatasvir in adults with hcv genotype 3 infection

Conditions: Chronic Hepatitis C; Hepatitis C Virus; Genotype 3 Hepatitis C Virus

Summary: the purpose of this study was to compare the safety and efficacy of abt-493/abt-530 to the combination of sofosbuvir (sof) and daclatasvir (dcv) in adults with genotype 3 (gt3) chronic hepatitis c virus (hcv) infection.

this study was a phase 3, randomized, open-label, active-controlled multicenter study to compare efficacy and safety of abt-493/abt-530 to sof and dcv in treatment-naïve chronic hcv gt3-infected participants without cirrhosis. the study consisted of 2 periods, a treatment period (participants received 8 or 12 weeks of abt-493/abt-530 or 12 weeks of sof with dcv) and a post-treatment period (participants who completed or prematurely discontinued the treatment period were followed for 24 weeks after their last dose of study drug to evaluate efficacy and to monitor hcv rna and the emergence and persistence of viral variants).

Eligibility criteria:
inclusion criteria: * male or female (of nonchildbearing potential, practicing total abstinence, sexually active with female partners only, or using allowed contraceptive methods) at least 18 years of age at time of screening. * screening laboratory result indicating hcv gt3 infection. * chronic hcv infection, defined as one of the following: * positive for anti-hcv antibody (ab) or hcv rna at least 6 months before screening; or * a liver biopsy consistent with chronic hcv infection; or * abnormal alanine aminotransferase (alt) levels for at least 6 months before screening. * hepatitis c virus treatment-naïve (i.e., participant had never received any anti-hcv treatment). * documented as noncirrhotic. exclusion criteria: * female who was pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner was pregnant or planning to become pregnant during the study. * recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could have precluded adherence to the protocol in the opinion of the investigator. * positive test result at screening for hepatitis b surface antigen (hbsag) or anti-human immunodeficiency virus ab (hiv ab). * hepatitis c virus genotyping performed during screening indicated co-infection with more than one hcv genotype. * any cause of liver disease other than chronic hcv infection. * consideration by the investigator, for any reason, that the participant was an unsuitable candidate to receive abt-493/abt-530, sof, or dcv. * history of severe, life-threatening, or other significant sensitivity to any excipients of the study drug. * previous use of any anti-hcv treatment.

Keywords: interferon free hepatitis c daclatasvir sovaldi hcv hepatitis c virus hepatitis c genotype 3 hep c sofosbuvir chronic hepatitis c daklinza
assessing the quality of life in adults with spinal deformity

Conditions: Scoliosis; Quality of Life

Summary: spinal deformities, such as scoliosis, can have a significant impact on the physical and psychological health of patients. over time, specific tools for this condition have been developed to investigate the extent of this impact, such as the srs-22 questionnaire and isyqol questionnaire. the latter was initially used for underage patients, but given that some of them continue their therapy and the monitoring beyond the age of 18, we have continued its use in these subjects as well. given the clinical usefulness and given the lack of questionnaires developed in the rasch environment for adults, we have extended the application of the isyqol questionnaire to the adult population. however, a comparison between the isyqol and srs-22 in adults has not yet been made. the objective of this study is to verify the validity of isyqol and to compare the properties of isyqol with those of the srs-22 questionnaire in adults with spinal deformity.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * diagnosis of idiopathic or degenerative scoliosis with ≥30 ° cobb curve exclusion criteria: * previous spinal surgery * previous and relevant illnesses, surgery or trauma
addressing social determinants of health in child obesity treatment using community health workers

Conditions: Child Obesity; Social Determinants of Health

Summary: the goal of this small pilot study is to test the feasibility of combining a three-month intervention of working with a community health worker (chw) to address social risk factors for patients prior to beginning a group weight management program for childhood obesity -- promoting health in teens and kids (phit kids)


Eligibility criteria:
inclusion criteria: * family must have one major social risk factor on the protocol for responding to \& assessing patients' assets, risks \& experiences (prapare) of the 14 modifiable risk factors * child aged 8 through 12 years of age * child with bmi% at 85th percentile or higher and less than the 120% of the 95th percentile (overweight or class 1 obesity) * child must live with parent/guardian at least 5 out of the 7 days on average (70% of the time) * child and parent able to speak english exclusion criteria: * child on medications known to cause ongoing weight gain (e.g., atypical anti-psychotics, chronic prednisone, insulin) * child on other medications know to affect weight if dose and bmi z-score has not been stable for 3 months. * diabetes or other disease that has a significant effect on diet, physical activity, or ability to take part in trial activities besides obesity (does not included treated or mild depression or anxiety, limited food allergies or mild physical activity limitations) * for parents: new mi, stroke or cancer diagnosis (excluding localized skin cancers) in past 6 months, history of bariatric surgery within the past 3 years, pregnancy in last 6 months or planned within 1 year * child or parent has significant developmental or cognitive impairments or other significant medical issue that would interfere with ability to participate or complete assessment * parent or child has significant physical limitation * parent/child planning to move to from children's mercy kansas city (cmkc) service area

Keywords: community health workers randomized trial pilot study child obesity treatment executive function
high frequency abr

Conditions: Hearing Loss, High-Frequency

Summary: this study is looking at a method called 'abr', which measures the electrical activity in the brain (brain waves) when we hear sounds. this study will look at the electrical activity in participants brains in response to high-pitched sounds. first, the investigators will find the quietest sounds the participants can hear. then the investigators will use 'abr' to measure the quietest sounds that trigger electrical activity in participants brains'. this is to find out if there is a difference between the quietest sounds participants can hear, and the quietest sounds that trigger these brain waves. we are also interested in finding out if having a hearing loss affects this.

the most common way of measuring how good someone's hearing is, is to play them sounds at different levels and ask them to respond when they can hear it, for example, by pressing a button when they hear a sound. however, some people such as young children and people with learning disabilities can't do this. so, we may use the abr technique instead. however, there are usually differences between abr thresholds (the quietest level of sound needed to trigger an electrical response in the brain) and behavioural hearing level thresholds (the quietest level sound is perceived). if we know what this difference usually is, we can use abr to work out how good someone's hearing is. we can already do this for most of the important pitches (aka frequencies) of sound, as typically experienced in the muffled sound in telephones. but we do not know the difference between abr and behavioural thresholds for high-pitched sounds that help make hearing crisper. so, that is what this study is trying to find out. to do this we need people with different hearing levels to participate in our study. including people with normal hearing and people with a hearing loss. we aim to recruit nearly 40 people in total with a range of different hearing levels.

Eligibility criteria:
inclusion criteria: * participant is able and willing to give informed consent. * participant is over 18. * hearing in the test ear of ≤90dbspl at 6 khz and 8 khz in pta * able and willing to perform pta reliably. * able and willing to sit still comfortably for the duration of an abr. exclusion criteria: * any conductive element to hearing loss (air-bone gap on pta of \>10db). * occluding wax, tm perforations or ear infections (on otoscopy) * ci or baha user * abnormal outer of middle ear
safety and immunogenicity of booster dose of an inactivated,adjuvanted whole-virion pandemic influenza(h5n1)vaccine

Conditions: Pandemic Influenza Vaccine; Prevention; Pandemic Influenza

Summary: a single center, non-randomized clinical trial in two-dose primed healthy adults to evaluate the safety and immunogenicity of a booster dose of an inactivated pandemic influenza (h5n1) vaccine (whole-virion, aluminium-adjuvanted).


Eligibility criteria:
inclusion criteria: * had received two-dose priming vaccination in previous phase i trial * be able to show legal identity card for the sake of recruitment * be able to understand and sign the informed consent. exclusion criteria: * woman： who breast-feeding or planning to become pregnant during the study * any history of allergic reactions to vaccines or eggs * autoimmune disease or immunodeficiency * diabetes mellitus (type i or ii), with the exception of gestational diabetes * serious angioedema episodes within the previous 3 years or requiring medication in the previous two years * hypertension that was not well controlled by medication or is more than 145/95 mmhg at enrollment * active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study * guillain-barre syndrome * women subjects with positive urinary pregnancy test * any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months * history of any blood products administration within 3 months before the dosing * administration of any other investigational research agents within 30 days before the dosing * administration of any live attenuated vaccine within 30 days before the dosing * administration of subunit or inactivated vaccines, e.g. pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing * be receiving anti-tb prophylaxis or therapy currently * axillary temperature \>37.0 centigrade at the time of dosing * psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years; disorder requiring lithium; or suicidal ideation occurring within five years prior to enrollment * any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.
patient-centered educational material to improve colposcopy adherence

Conditions: Cervical Cancer Screening

Summary: the long-term goal is to develop, test, and disseminate a social needs navigator intervention that improves colposcopy adherence. based on stakeholder feedback, this study addresses the need to include patient-centered educational material to the navigator program in order to improve patients' health literacy regarding cervical cancer prevention.

the investigators will evaluate the effectiveness of the colposcopy educational material. the investigators aim to recruit 25 newly referred colposcopy patients before their appointment, ask them to take a 5-minute test about their knowledge of colposcopy, have them view an online demo of the educational resources, and then retake the test.

Eligibility criteria:
inclusion criteria: * age 21 years or older * abnormal cervical screen confirmed by cytology or pathology * referred to washington university school of medicine (wusm) colposcopy clinic exclusion criteria: * history of cervical cancer * unable to consent

Keywords: cervical cancer screening colposcopy patient education